PMN442 / ProMIS Neurosci - LARVOL DELTA

Pipeline Progress…Future Activities and Upcoming Milestones (GlobeNewswire) - "PMN267 (ALS/FTD): The Company’s program targeting misfolded TDP-43 has been humanized in a human IgG1 framework and is progressing through investigational new drug (IND)-enabling studies; PMN442 (Parkinson’s Disease, Dementia with Lewy Bodies, Multiple System Atrophy): The Company’s lead candidate targeting pathogenic alpha-synuclein has been humanized and is advancing toward IND-enabling studies based on its selective binding activity....Participation and presentations at multiple investor and medical conferences, including Clinical Trials on AD (CTAD)."

Preclinical • Amyotrophic Lateral Sclerosis • Frontotemporal Lobar Degeneration • Lewy Body Disease • Multiple System Atrophy • Parkinson's Disease

Key Pipeline Programs (GlobeNewswire) - "We have accelerated the development of a subcutaneous formulation of PMN310 and established a dedicated development plan, reflecting our conviction in the potential of this approach to improve patient experience and strengthen the asset's competitive profile...PMN267 has been humanized in a human IgG1 framework for IND-enabling studies....ProMIS selected PMN442 as the lead candidate antibody for PD and other synucleinopathies based on its selective binding and protective activity against pathogenic forms of alpha-synuclein. It has been humanized in a human IgG1 framework for IND-enabling studies."

Pipeline update • Preclinical • Amyotrophic Lateral Sclerosis • Lewy Body Disease • Multiple System Atrophy • Parkinson's Disease

Key Pipeline Programs (GlobeNewswire) - "PMN267 is a humanized IgG1 antibody directed against toxic misfolded TDP-43 as a potential therapeutic target for ALS and is ready to progress to IND-enabling studies....PMN442 is a humanized IgG1 antibody and is ProMIS’s lead candidate for PD, MSA and other synucleinopathies based on its selective binding and protective activity against pathogenic forms of alpha-synuclein and is ready to progress to IND-enabling studies."

Preclinical • Amyotrophic Lateral Sclerosis • Multiple System Atrophy • Parkinson's Disease • Tauopathies And Synucleinopathies

ProMIS Neurosciences Announces Second Quarter 2021 Results (GlobeNewswire) - “In Alzheimer’s we will restart IND enabling work for PMN310, our antibody highly selective for toxic oligomers of amyloid. That selectivity may prove to give PMN310 significant competitive advantages in safety and efficacy over products from Biogen, Lilly, and Eisai that appear to provide benefit slowing the progression of Alzheimer’s disease....We will also further advance our alpha-synuclein program with further in vivo and in vitro validation, targeting diseases like Parkinson’s disease and Multiple System Atrophy.”

Preclinical • Alzheimer's Disease • CNS Disorders • Multiple System Atrophy • Parkinson's Disease